The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension provide comprehensive recommendations for the management of this condition. The guidelines were developed by a joint task force of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), with support from various other organizations. They aim to assist healthcare professionals in selecting the best management strategies for patients with pulmonary hypertension (PH), considering the impact on outcomes and the risk-benefit ratio of diagnostic and therapeutic approaches. PH is classified into five groups based on its underlying causes. Group 1 includes pulmonary arterial hypertension (PAH), while groups 2-5 are associated with left heart disease, lung diseases, chronic thromboembolic pulmonary hypertension (CTEPH), and other mechanisms. The guidelines emphasize the importance of accurate diagnosis, which involves a combination of clinical evaluation, imaging, and right heart catheterization. They also provide detailed recommendations for the treatment of each group, including drug therapies, supportive care, and interventions such as balloon atrial septostomy and transplantation. The guidelines highlight the importance of expert referral centers for the management of PH patients and emphasize the need for multidisciplinary approaches. They also address the importance of genetic factors in the development of PH, particularly in familial cases. The guidelines include updated diagnostic algorithms and emphasize the need for regular follow-up and monitoring of patients. The guidelines also provide information on the epidemiology of PH, including its prevalence and risk factors. They emphasize the importance of early diagnosis and treatment to improve outcomes. The guidelines are accompanied by a detailed table of contents and appendices, providing additional information on the classification, diagnosis, and treatment of PH. The guidelines are intended for use in clinical practice and are not intended for commercial use. They are available for personal and educational use only, and permission is required for any reproduction or translation.The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension provide comprehensive recommendations for the management of this condition. The guidelines were developed by a joint task force of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), with support from various other organizations. They aim to assist healthcare professionals in selecting the best management strategies for patients with pulmonary hypertension (PH), considering the impact on outcomes and the risk-benefit ratio of diagnostic and therapeutic approaches. PH is classified into five groups based on its underlying causes. Group 1 includes pulmonary arterial hypertension (PAH), while groups 2-5 are associated with left heart disease, lung diseases, chronic thromboembolic pulmonary hypertension (CTEPH), and other mechanisms. The guidelines emphasize the importance of accurate diagnosis, which involves a combination of clinical evaluation, imaging, and right heart catheterization. They also provide detailed recommendations for the treatment of each group, including drug therapies, supportive care, and interventions such as balloon atrial septostomy and transplantation. The guidelines highlight the importance of expert referral centers for the management of PH patients and emphasize the need for multidisciplinary approaches. They also address the importance of genetic factors in the development of PH, particularly in familial cases. The guidelines include updated diagnostic algorithms and emphasize the need for regular follow-up and monitoring of patients. The guidelines also provide information on the epidemiology of PH, including its prevalence and risk factors. They emphasize the importance of early diagnosis and treatment to improve outcomes. The guidelines are accompanied by a detailed table of contents and appendices, providing additional information on the classification, diagnosis, and treatment of PH. The guidelines are intended for use in clinical practice and are not intended for commercial use. They are available for personal and educational use only, and permission is required for any reproduction or translation.